Articles related to Pulmonology

In this podcast/article from KevinMD.com, the author questions how FIGS – a design-driven medical apparel company – let a flagrantly offensive advertisement against DOs get published, in addition to other criticism: “We should also ponder how – despite 150 years of DO education within the US – we’ve failed to correct the systemic discrimination against osteopathic students and physicians.”

Medical practices incorporate digital apps to improve online scheduling, send appointment reminders, and provide telemedicine options. And physicians now have entire medical libraries at their fingertips to confirm a diagnosis, check drug interactions, and collaborate with other HCPs. Here are some of the most popular medical apps for doctors, nurses, and medical students.

To help ready physicians with sound, scientific knowledge—untarnished by political views—essential to combating COVID-19, the Annals of Internal Medicine and the American College of Physicians hosted the COVID-19 Vaccine Forum on 10/16/20 to offer current, evidence-based information related to the science, approval processes, and development of clinical recommendations for vaccines.

Medscape’s National Physician Burnout and Suicide Report 2020, which surveyed more than 15,000 physicians (prior to the COVID-19 pandemic), found 42% of those interviewed admitted to feeling burned out. Burnout has many causes, but also many solutions. Here are three tips to help you cope on an individualized level.

In this article/podcast from KevinMD.com, the physician authors describe their distress upon hearing and reading the recent disparaging comments about osteopathic medicine, which attacked Navy Commander Dr. Sean Conley, DO, the Physician of the President: “When someone challenges the validity of a legitimate medical degree, the entire house of medicine is under attack.”

The US Food and Drug Administration (FDA) approval – the first for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma – was based on a randomized, open-label trial, of 605 patients. The endpoint was to determine if the nivolumab-ipilimumab combo improved overall survival compared to chemotherapy.